Accessory Pathway Antegrade Effective Refractory Period Among Wolff Parkinson White Patients: the Risk in Relation to the Location

Accessory Pathway Antegrade Effective Refractory Period Among Wolff Parkinson White Patients: the Risk in Relation to the Location

Recruitment Information:

Seeking volunteers with following diagnosis: PD Study Type:
Eligible Ages: 0 - 100 Status: Not yet recruiting
Time Since Diagnosis: Any may be eligible Study Focus:

Study Purpose:

To correlate the antegrade effective refractory period of the accessory pathway with its anatomical location in the heart. To investigate whether the accessory pathway location can predict the high risk nature of the accessory pathway

Find a Site Location and Contact the Trial Team

More Details

The Wolf-Parkinson-White (WPW) syndrome is a clinical entity characterized by the presence of ≥1 accessory pathways between the atria and the ventricles pre-disposing patients to arrhythmias. Anterograde conduction through the accessory pathway leads to preexcitation of the ventricles and a delta wave in the ECG. The prevalence of preexcitation in the general population has been estimated to be 1 to 3 in 1000 individuals. Although most asymptomatic patients with pre-excitation have a good prognosis, there is also a lifetime risk of malignant arrhythmias and SCD, estimated to be 0.1 % per patient year. - More worrisome is the fact that this event can be the first manifestation of the disease in up to 53 % of patients. - Atrial fibrillation (AF) can be a life-threatening arrhythmia in the WPW syndrome if the AV AP has a short anterograde refractory period (RP), allowing too many atrial impulses to be conducted to the ventricle. - This will result in very high ventricular rates with possible deterioration into ventricular fibrillation (VF) and sudden death. - Parameters proved to indicate high risk AP include AP effective refractory period

Phase: Lead Sponsor: Assiut University
Trial ID: 006482 Sponsor Type: Other
Primary Country: United States Additional Collaborators or Sponsors:
Estimated Enrollment: 35 Study Start Date: December 2019
Estimated Study Completion Date: March 2023 Source: ClinicalTrials.gov
Study Website:

More Inclusion & Exclusion Criteria

Share This Trial


Fox Trial Finder strives to make all trial postings as accurate and complete as possible. If you believe any of the information on this page is not accurate, click here to contact us. Thank you for your support.

Choose your location

Please select a Trial Location.
x

Confirmation

You have favorited this trial!

This trial will be listed in the "Favorites" category of your dashboard.
x

Confirmation

You are not interested.

This trial will be listed in the "Not Interested" category on your dashboard. You can click "Interested" if you change your mind.
x

Message to Trial Coordinator

Your message was sent.

Your message was sent to the trial team at the location you selected. Check your dashboard for a response.

Login to Fox Trial Finder

Please enter your email address and password to access your My Fox Trial Finder dashboard.



*indicates required field.
x

Contact Fox Trial Finder

What best describes you?





*indicates required field.
x